The Risks and Benefits of 5α-Reductase Inhibitors for Prostate Cancer Prevention
TLDR 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
In December 2010, the FDA's Oncologic Drugs Advisory Committee convened to discuss the potential benefits and risks associated with 5α-reductase inhibitors, particularly in the context of prostate cancer prevention. The committee focused on the dual nature of these drugs, which may prevent prostate cancer but also potentially increase the risk of high-grade cancers. The document from July 14, 2011, likely provided an overview of the committee's findings and discussions, but without additional details from the document, the specific conclusions or recommendations made by the FDA at that time cannot be summarized.
